Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period

      This image opens in the lightbox

      News provided by

      Visiongain

      18 Mar, 2020, 10:00 GMT

      Share this article

      Share this article


      - Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

      - Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

      LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

      How this report will benefit you

      Read on to discover how you can exploit the future business opportunities emerging in this sector.

      In this brand new 236-page report you will receive 180 tables and 121 figures– all unavailable elsewhere.

      The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

      By ordering and reading our brand-new report today you stay better informed and ready to act.

      To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

      Report Scope

      • Global Rheumatoid Arthritis Market forecast from 2020-2030

      • Revenue forecasts for the Rheumatoid Arthritis Market by Drug Class from 2020-2030:
      • Biologics
      • Non-Biologics: NSAIDs, sDMARDs, Others

      • Revenue forecasts for the Rheumatoid Arthritis Market by Drugs from 2020-2030:
      • Humira
      • Enbrel
      • Remicade
      • Rituxan/MabThera
      • Simponi/Simponi Aria
      • Orencia
      • Actemra/Roactemra
      • Cimzia
      • Celebrex
      • Xeljanz
      • Arcoxia
      • Others

      • Revenue forecasts for the Rheumatoid Arthritis Market by Region from 2020-2029:
      • North America: U.S., Canada
      • Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe
      • Asia-Pacific: Japan, China, India, Rest of Asia-Pacific
      • Latin America: Brazil, Mexico, Rest of Latin America
      • Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

      • Profiles of these selected leading companies:
      • AbbVie
      • Amgen, Inc.
      • Bristol-Myers Squibb
      • Eli Lilly and Company
      • F. Hoffmann-La Roche Ltd
      • Johnson & Johnson
      • Merck & Co.
      • Novartis AG
      • Pfizer
      • Sanofi S.A.
      • UCB

      • Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

      • The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

      • Key questions answered by this report:
      • How is the Rheumatoid Arthritis drugs market evolving?
      • What is driving and restraining the Rheumatoid Arthritis drugs market?
      • What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018?
      • How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
      • How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030?
      • Which individual therapies will prevail and how will these shifts be responded to?
      • What will be the main driver for the overall market from 2020 to 2030?
      • How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030?
      • Who are the leading players and what are their prospects over the forecast period?
      • How will the industry evolve during the period between 2020 and 2030?

      To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

      Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

      Companies covered in the report include:

      4SC
      AbbVie
      Abivax
      Ablynx NV Sanofi
      Adheron Therapeutics, Inc.
      Akari Therapeutics Plc
      Alder Biopharmaceuticals
      Amgen
      Anacor
      Araim Pharmaceuticals, Inc.
      argenx
      Artax Biopharma, Inc.
      Astellas Pharma Inc
      Baxalta Incorporated
      Biocon Ltd.
      Biogen
      Bioxpress Therapeutics
      Boehringer Ingelheim
      Bristol-Myers Squibb
      Cadila Healthcare
      Cambridge Biotechnology Ltd.
      CASI Pharmaceuticals
      Catabasis Pharmaceuticals
      Celltex Therapeutics Corp.
      Celltrion, Inc.
      ChemoCentryx
      Chugai Pharmaceutical Co., Ltd.
      Coherus BioSciences Inc
      Covagen AG
      Cyclacel Pharmaceuticals
      Cyxone AB
      Daiichi Sankyo
      DePuy Synthes
      Dr Reddy's Laboratories
      Eli Lilly
      Epirus Biopharmaceuticals
      Five Prime Therapeutics
      Fresenius Kabi
      Fujifilm Corporation
      Galapagos NV
      Galderma
      Genentech
      Gerresheimer
      Giaconda Ltd.
      Gilead Sciences, Inc.
      GlaxoSmithKline plc
      Glenmark Pharmaceuticals Ltd.
      Hanmi Pharmaceutical Co Ltd.
      Hospira
      Immunomedics
      Incyte Corporation
      Innate Pharma - IPO Pending
      Intas
      Italfarmaco SpA
      Izana Bioscience Ltd.
      Janssen Biologics
      Johnson & Johnson
      Kadmon Holdings
      Kyowa Hakko Kirin Co Ltd
      Lycera Corporation
      Medigene
      Merck & Co.
      Mesoblast
      Mitsubishi Tanabe Pharma
      Momenta
      Morphosys
      Mycenax Biotech
      Mylan NV
      Neovacs SA
      NeuBase Therapeutics, Inc.
      Novo Nordisk
      Onyx Pharmaceuticals, Inc.
      OphthaliX, Inc. Can-Fite BioPharma Ltd
      Outlook Therapeutics, Inc.
      Padlock
      Pfizer
      Philogen SpA
      Principia Biopharma, Inc.
      Protalex, Inc.
      Protalix BioTherapeutics
      Ra Pharmaceuticals Inc.
      Regeneron Pharmaceuticals, Inc.
      Roche
      Samsung Bioepis
      Sanofi
      Shanghai CP Guojian Pharmaceuticals
      Spirig Pharma A.G.
      Takeda Pharmaceuticals
      Theravance Biopharma, Inc.
      TiGenix NV Takeda Pharmaceutical
      UCB
      Vitaeris Inc,
      Xencor
      XOMA
      Zynerba Pharmaceuticals

      Other Organisations Mentioned in the Report
      American College of Rheumatology
      Nurses Health
      WHO
      National Rheumatoid Arthritis Society
      United Nations
      US Patent Office
      European Commission
      U.S. Food and Drug Administration (FDA)
      Committee for Medicinal Products for Human Use (CHMP)
      Centers for Disease Control and Prevention (CDC)
      World Bank
      Arthritis Foundation
      Canadian Arthritis Society
      World Arthritis Day
      National Rheumatoid Arthritis Society
      Servizio Sanitario Nazionale (SSN)
      Ministry of Health
      National Institute on Aging
      National Center for Biotechnology Information
      Unified Health System
      ANVISA (Agência Nacional de Vigilância Sanitária)
      African League of Associations in Rheumatology
      International League of Associations for Rheumatology
      Government of Abu Dhabi
      Johns Hopkins
      Bumrungrad
      Cleveland Clinic
      Vamed
      Emirates Arthritis Foundation
      National Treasury of Republic of South Africa
      European Medicines Agency
      National Institute for Health Research (NIHR)
      National Institute for Health and Care Excellence (NICE)
      Institute for Quality and Efficiency in Healthcare
      Institut fϋr Qualität und Wirtschaftlichkeit im Gesundheitswesen – IQWiG

      To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com 

      Related reports:

      Global Bioreactors Market 2020-2030

      Next-Generation Biologics Market Forecast to 2029

      Global Biosimilars and Follow-On Biologics Market 2019-2029

      Pharma Wholesale and Distribution Market Forecasts 2020-2030

      Translational Regenerative Medicine Market Forecast 2020-2030

      Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.